59 completed, 4 terminated, 2 unknown, 1 recruiting. 20 Phase 4, 17 Phase 3, 14 Phase 2, 10 Not applicable, 4 Phase 1.
Follow Salmeterol: new trials by email Literature Review of Salmeterol trials Research Report on Salmeterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Salmeterol Effect on Exercise Performance Salmeterol, Placebo - Healthy | Not applicable | Recruiting | University of Copenhagen | 36 | 2024-10-31 | 2025-04-09 |
| Replication of the POET-COPD Trial in Healthcare Claims Data Salmeterol, Tiotropium - Chronic Obstructive Pulmonary Disease | Completed | Brigham and Women's Hospital | 8716 | 2020-09-22 | 2023-07-27 | |
| The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Tiotropium, Olodaterol, Fluticasone propionate - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 302 | 2017-08-14 | 2020-04-16 |
| Cardiovascular Function in COPD Patients Tiotropium, Olodaterol, Fluticasone propionate - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 76 | 2017-03-29 | 2019-08-16 |
| Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma Personalised medicine (Salmeterol), Personalised medicine (Montelukast), Standard care - Asthma | Not applicable | Completed | University of Sussex | 241 | 2016-02-01 | 2020-04-16 |
| Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects LIPO-202, Placebo - Central Abdominal Bulging | Phase 2 | Completed | Neothetics, Inc | 120 | 2015-09-01 | 2015-12-24 |
| A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma Fluticasone Furoate, Vilanterol, Fluticasone propionate - Asthma | Phase 3 | Completed | GlaxoSmithKline | 423 | 2015-07-09 | 2019-01-14 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Evofem Inc. | 793 | 2015-04-09 | 2019-01-07 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Neothetics, Inc | 800 | 2015-04-01 | 2016-01-08 |
| Pharmacological Properties of Salmeterol Salmeterol - Pharmacokinetics in Healthy Young Men | Phase 4 | Completed | University of Copenhagen | 11 | 2014-09-01 | 2017-01-31 |
| Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate Salmeterol, fluticasone propionate - Healthy | Phase 1 | Completed | Kindeva Drug Delivery | 52 | 2014-07-01 | 2022-06-15 |
| Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study Formoterol Fumarate, Salmeterol - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Completed | University of Milan | 49 | 2014-07-01 | 2015-07-10 |
| Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD Budesonide, Fluticasone, Indacaterol - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 222 | 2014-05-30 | 2017-04-18 |
| Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients fluticasone propionate, salmeterol, placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 229 | 2013-10-01 | 2016-02-12 |
| Dose-Response of Salmeterol in Children Advair Diskus100/50 µg, Flovent Diskus 100 µg, Methacholine Chloride - Asthma | Phase 4 | Completed | University of Florida | 10 | 2013-08-01 | 2014-10-07 |
| Effects of Particle Size in Small Airways Dysfunction Formoterol, Salmeterol - Asthma | Phase 4 | Completed | University of Dundee | 17 | 2013-07-01 | 2019-04-12 |
| Dose Ranging Study Drug: salmeterol xinafoate, Drug: Placebo - Periumbilical Subcutaneous Adipose Tissue Reduction | Phase 2 | Completed | Neothetics, Inc | 472 | 2013-02-01 | 2015-03-26 |
| Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) QMF149, Salmeterol - COPD | Phase 2 | Completed | Novartis Pharmaceuticals | 629 | 2012-11-01 | 2014-11-17 |
| Effects of Salmeterol on Autonomic Nervous System Salmeterol - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | GlaxoSmithKline | 32 | 2012-07-01 | 2014-04-11 |
| Long-acting Beta Agonist Step Down Study Fluticasone/Salmeterol Diskus, Fluticasone Diskus - Asthma | Phase 4 | Completed | Johns Hopkins University | 459 | 2012-03-01 | 2017-04-25 |
Showing 20 of 67. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (39) · Asthma (17) · Bronchitis, Chronic (3) · Emphysema (3) · Dyspnea (2) · Respiratory Aspiration (2) · Asthma, Exercise-Induced (1) · Cystic Fibrosis (1) · Inflammation (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Quadriplegia (1) · Rhinitis, Allergic (1) · Spinal Cord Injuries (1) · Virus Diseases (1)
Boehringer Ingelheim (14) · GlaxoSmithKline (10) · Novartis Pharmaceuticals (5) · Brigham and Women's Hospital (4) · Neothetics, Inc (3) · Chiesi Farmaceutici S.p.A. (2) · Novartis (2) · Pfizer (2) · Sumitomo Pharma America, Inc. (2) · University of Copenhagen (2) · University of Dundee (2) · University of Milan (2) · Arthur F Gelb MD (1) · AstraZeneca (1) · Dartmouth-Hitchcock Medical Center (1)
United States (32) · Germany (16) · United Kingdom (10) · Italy (9) · Netherlands (9) · Denmark (8) · Sweden (8) · Belgium (7) · Spain (7) · Finland (6) · Hungary (6) · France (5) · Slovakia (5) · South Africa (5) · Canada (4)
Maria Feldman (3) · Elliot Israel, MD (2) · Adam Wanner, MD (1) · Alberto Papi, MD (1) · Arthur F Gelb, MD (1) · Arvind Deva Manoharan, MBChB (1) · Barry Make, MD (1) · Brian J Lipworth, MD (1) · Brian Lipworth, MD (1) · Chang-Keun Kim, MD, PhD (1)
PMID 23613569, PMID 10903223, PMID 15500895, PMID 15806036, PMID 16322642, PMID 16772309, PMID 19436693, PMID 19820080, PMID 19932356, PMID 20705799, PMID 20850959, PMID 21428765, PMID 21980058, PMID 22192967, PMID 22235841, PMID 23188489, PMID 23745526, PMID 24154513, PMID 24168767, PMID 24228710, PMID 24461901, PMID 25924990, PMID 26100349, PMID 26220533, PMID 26505596, PMID 28626983, PMID 28982774, PMID 29775687, PMID 29863899, PMID 30053956, PMID 33479111, PMID 36472162, PMID 37347518, PMID 41134080, PMID 7913549, PMID 9310023, PMID 9664089
2015 (1), M01RR000036 (1), U10HL074073 (1), U10HL074204 (1), U10HL074208 (1), U10HL074212 (1), U10HL074218 (1), U10HL074225 (1), U10HL074227 (1), U10HL074231 (1)